LEADER 04185nam  2200481   450 
001 9910808459203321
005 20230807205518.0
010   $a1-68108-134-2
035   $a(CKB)3710000000531583
035   $a(EBL)4412591
035   $a(MiAaPQ)EBC4412591
035   $a(EXLCZ)993710000000531583
100   $a20160614d2015      uy|            0
101 0 $aeng
135   $aur|n|---|||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aDown syndrome children-- and update /$fedited by Mohammed Al-Biltagi, associate professor of pediatrics, Tanta University, Egypt
210  1$aSharjah :$cBentham Science Publishers, Limited,$d[2015]
215   $a1 online resource (486 p.)
300   $aIncludes index.
311   $a1-68108-135-0 
327   $aCONTENTS; FOREWORD ; PREFACE ; List of Contributors ; Epidemiology and Prevalence of Down Syndrome ; 1. INTRODUCTION; 2. FACTORS AFFECTING THE RISK OF DOWN SYNDROME; 2.1. Maternal Age at Birth; 2.2. Altered Recombination Patterns Along Chromosome 21; 2.3. Maternal Grandmother Age; 2.4. Paternal Age; 2.5. Consanguinity; 2.6. Parity and Reproductive Function of the Mother; 2.7. Interval Between Pregnancies; 2.8. Previous Child with Down Syndrome; 2.9. Multiple Versus Singleton Pregnancies; 2.10. Environmental Factors
327   $a2.10.1. Impact of Prenatal Diagnosis on the Prevalence of Down Syndrome and Rate of Pregnancy Termination2.10.2. Socioeconomic Status; 2.10.3. Exposure to Chemical Toxins, Drugs and Diseases; 3. PREVALENCE OF DOWN SYNDROME; 3.1. Prevalence in Africa; 3.2. Prevalence in Arab Worlds; 3.3. Prevalence in Asia; 3.4. Prevalence in Australia; 3.5. Prevalence in Europe; 3.6. Prevalence in North America (Fig. 4); 3.7. Prevalence in South America; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Genetics of Down Syndrome: An Update ; 1. INTRODUCTION: CHROMOSOMAL BASIS OF DOWN SYNDROME
327   $a2. ETIOLOGY AND ORIGIN OF EXTRA CHROMOSOME 212.1. Nondisjunction Trisomy 21; 2.2. Robertsonian Translocation; 2.3. Mosaicism; 3. MOLECULAR GENETICS; 3.1. Genes Involved in Cognitive Impairment; 3.2. Genes Involved in Hematological Malignancies; 3.2.1. TAM: A Unique Hematological Finding in DS; 3.2.2. JAK2 Associated ALL in DS; 3.2.3. CBER1 Gene and Anthracycline- Related Cardiotoxicity in DS; 3.3. Genes Involved in Congenital Heart Disease (CHD); 3.4. Genes Involved in Immunological Dysfunctions; 4. THE BLESSING EFFECT OF EXTRA CHROMOSOME 21 ; 4.1. Protective Effects Against Solid Malignancy
327   $a4.2. DS and Diabetic Retinopathy4.3. Anticancer Therapy; 4.4. Anti-Inflammatory Effect; 4.5. Vascular Anomalies; 4.6. Neuroprotective Effect!!!; 4.7. Lucky Mothers??; 5. GENE THERAPY IN DS: SILENCING THE EXTRA CHROMOSOME; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Neonates with Down Syndrome ; 1. INTRODUCTION; 2. DIAGNOSIS OF DOWN SYNDROME; 2.1. Antenatal Diagnosis; 2.1.1. Prenatal Screening ; 2.1.2. Invasive Prenatal Diagnosis; 2.2. Postnatal Diagnosis; 2.3. Informing the Parents; 3. GROWTH AND DEVELOPMENTAL CHARACTERISTICS OF NEONATES WITH DS
327   $a4. MEDICAL PROBLEMS COMMON IN NEONATES WITH DS4.1. Congenital Heart Diseases; 4.2. Gastrointestinal Abnormalities; 4.3. Upper Airway Abnormalities; 4.4. Respiratory Abnormalities; 4.5. Endocrine Disorders; 4.6. Ophthalmic Disorders; 4.7. Hematologic Disorders; 4.8. Orthopedic Disorders; 4.9. Urinary Tract Disorders; 4.10. Dermatological Disorders; 4.11. Neurological Disorders; 4.12. Dental Disorders; 5. FEEDING NEONATE AND INFANT WITH DS; 5.1. Breastfeeding; 5.2. Bottle Feeding; 5.3. Weaning; 5.4. Feeding Problems for Neonates and Infants
327   $a5.5. Nutritional Intervention in Neonates and Infants with DS
606   $aDown syndrome
606   $aChild development
606   $aDown syndrome$xPatients
615  0$aDown syndrome.
615  0$aChild development.
615  0$aDown syndrome$xPatients.
702   $aAl-Biltagi$b Mohammed
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910808459203321
996   $aDown syndrome children-- and update$93935413
997   $aUNINA